EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report

Aakash Desai, Sagar Rakshit, Radhika Bansal, Yash Ashara, Ashley Potter, Rami Manochakian, Yanyan Lou, Yujie Zhao, Vinicius Ernani, Panos Savvides, Anna Schwecke, Nicole Moffett und 8 weitere

Cancer Treatment and Research Communications · 2023

DOI: 10.1016/j.ctarc.2023.100743 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2023. Verfasst von Aakash Desai und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Chemical and Drug Induced Liver Injury. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: We evaluated the risk factors and outcomes for patients who experienced hepatotoxicity after use of sotorasib in KRAS G12C mutated NSCLC. METHODS: Retrospective review of medical records of patients with KRAS G12C mutated NSCLC who received sotorasib between May 28th, 2021, and December 31st, 2021 across all Mayo Clinic sites, with follow up until December 31st, 2022. RESULTS: Thirty-one patients received sotorasib as standard of care treatment. Grade 3 or higher hepatoxicity was seen in 32% (10/31) patients presenting at a median of 51 days (range, 27-123) of sotorasib initiation. Baseline demographics were comparable between patients with and without ≥grade 3 hepatotoxicity, except for presence of CNS metastases and time from prior immune checkpoint inhibitor (ICI) treatment. Improvement in liver tests was observed in all patients after stopping sotorasib, and it was restarted at a lower dose in 8 patients. Despite dose reduction, hepatotoxicity requiring sotorasib discontinuation occurred in 2 patients. Twenty-eight of 31 patients had received prior ICI. Median time from prior ICI therapy was 69 days (range, 4-542). Rates of ≥grade 3 hepatoxicity were 75% (3/4), 64% (7/11) and 0% (0/13) for patients who received ICI within 30 days, 31-90 days and >90 days. None of the 3 patients without prior ICI exposure developed hepatoxicity. The median PFS and OS were 3.9 months and 9.9 months respectively. CONCLUSION: One-third of patients developed grade 3 or higher sotorasib induced hepatotoxicity. Risk of hepatotoxicity was higher in patients who received sotorasib within 90 days of ICI treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsChemical and Drug Induced Liver InjuryHumansImmune Checkpoint InhibitorsProto-Oncogene Proteins p21(ras)PiperazinesPyridinesPyrimidines

Stichwörter der Autor:innen

HepatotoxicityImmunotherapySotorasib

Substanzen

Immune Checkpoint InhibitorsProto-Oncogene Proteins p21(ras)sotorasibPiperazinesPyridinesPyrimidines

Autor:innen und Institutionen

  • Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
  • Department of Medicine, Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL, USA.
  • Department of Medical Oncology, Mayo Clinic, Scottsdale, AZ, USA.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA. Electronic address: dimou.anastasios@mayo.edu.

Zitieren

APA

Desai, A., Rakshit, S., Bansal, R., Ashara, Y., Potter, A., Manochakian, R., Lou, Y., Zhao, Y., Ernani, V., Savvides, P., Schwecke, A., Moffett, N., Hocum, C., Leventakos, K., Adjei, A., Marks, R., Molina, J., Mansfield, A. S., Chen, Z. M., & Dimou, A. (2023). Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2023.100743

Vancouver

Desai A, Rakshit S, Bansal R, Ashara Y, Potter A, Manochakian R, et al. Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report. Cancer Treatment and Research Communications. 2023. doi:10.1016/j.ctarc.2023.100743

BibTeX
@article{Desai2023,
  author = {Desai, Aakash and Rakshit, Sagar and Bansal, Radhika and Ashara, Yash and Potter, Ashley and Manochakian, Rami and Lou, Yanyan and Zhao, Yujie and Ernani, Vinicius and Savvides, Panos and Schwecke, Anna and Moffett, Nicole and Hocum, Craig and Leventakos, Konstantinos and Adjei, Alex and Marks, Randolph and Molina, Julian and Mansfield, Aaron S and Chen, Zong-Ming and Dimou, Anastasios},
  title = {Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report},
  journal = {Cancer Treatment and Research Communications},
  year = {2023},
  doi = {10.1016/j.ctarc.2023.100743}
}
Kostenlos starten →